Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection

Show full item record



Permalink

http://hdl.handle.net/10138/166369

Citation

Mustanoja , S , Metso , T M , Putaala , J , Heikkinen , N , Haapaniemi , E , Salonen , O & Tatlisumak , T 2015 , ' Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection ' , Brain and Behavior , vol. 5 , no. 8 , 00349 . https://doi.org/10.1002/brb3.349

Title: Helsinki experience on nonvitamin K oral anticoagulants for treating cervical artery dissection
Author: Mustanoja, Satu; Metso, Tiina M.; Putaala, Jukka; Heikkinen, Noora; Haapaniemi, Elena; Salonen, Oili; Tatlisumak, Turgut
Contributor: University of Helsinki, Department of Neurosciences
University of Helsinki, Neurologian yksikkö
University of Helsinki, Neurologian yksikkö
University of Helsinki, Department of Neurosciences
University of Helsinki, Clinicum
University of Helsinki, Clinicum
Date: 2015-08
Language: eng
Number of pages: 4
Belongs to series: Brain and Behavior
ISSN: 2162-3279
URI: http://hdl.handle.net/10138/166369
Abstract: BackgroundCervical artery dissection (CeAD) patients with or without stroke are frequently treated with either antiplatelet agents or vitamin K antagonists (VKAs), but few data are reported on the use of nonvitamin K oral anticoagulants (NOACs). MethodsBetween November 2011 and January 2014, we recorded data from patients with a stroke due to vertebral (VAD) or internal carotid artery dissection (ICAD). Patients using oral anticoagulants were included in the study and were divided into two treatment groups: patients using NOACs and those using VKAs. Excellent outcome was defined on modified Rankin Scale (mRS) 1 at 6months. ResultsOf 68 stroke patients (67% male; median age 45 [39-53]), six (8.8%; two with VAD and four with ICAD) were treated with NOACs: three with direct thrombin inhibitor dabigatran and three with direct factor Xa inhibitor rivaroxaban. National Institutes of Health Stroke Scale score at baseline was 4 (3-7) in the NOAC versus 2 (1-7) in the VKA groups. Complete recanalization at 6months was seen in most patients in the NOAC (n=5; 83%) and VKA (n=34; 55%) groups. All the patients using NOACs had mRS 1 at 6months and none had an intracerebral hemorrhage (ICH). In the VKA group most patients (n=48; 77%) had mRS 1, one patient (1.7%) had an ICH and one died. ConclusionsIn this small, consecutive single-center patient sample treating ischemic stroke patients with CeAD with NOACs did not bring up safety concerns and resulted in similar, good outcomes compared to patients using VKAs.
Subject: Acute stroke
anticoagulation
cervical arterial dissection
NONVALVULAR ATRIAL-FIBRILLATION
WARFARIN
RISK
3124 Neurology and psychiatry
Rights:


Files in this item

Total number of downloads: Loading...

Files Size Format View
Mustanoja_et_al_2015_Brain_and_Behavior.pdf 55.15Kb PDF View/Open

This item appears in the following Collection(s)

Show full item record